Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Value of Circulating Tumor DNA Dosing in Patients in Neoadjuvant Breast Neoplasia

NCT05050890 is registered in ClinicalTrials.gov with Instituto Brasileiro de Controle do Cancer as lead sponsor.

NCT NCT05050890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05050890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Value of Circulating Tumor DNA Dosing in Patients in Neoadjuvant Breast Neoplasia
Lead sponsor
Instituto Brasileiro de Controle do Cancer
Phase
Observational
Overall status
Unknown status
Start date
August 5, 2020
Completion date
February 28, 2022
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm